Edition:
United Kingdom

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

84.78USD
16 Aug 2019
Change (% chg)

$0.84 (+1.00%)
Prev Close
$83.94
Open
$84.77
Day's High
$85.08
Day's Low
$84.27
Volume
1,618,713
Avg. Vol
1,480,788
52-wk High
$88.76
52-wk Low
$63.60

Latest Key Developments (Source: Significant Developments)

Abbott CEO Says FreeStyle Libre Can Achieve $5 Bln In Sales "In A Reasonable Time"
Wednesday, 17 Jul 2019 

July 17 (Reuters) - Abbott Laboratories ::ABBOTT LABORATORIES SAYS HAS RESEARCH AND DEVELOPMENT PROGRAMS UNDERWAY NOT ONLY FOR ENHANCEMENT AND EXPANSION OF FREESTYLE LIBRE, BUT ALSO IN CATEGORIES BEYOND DIABETES.ABBOTT LABORATORIES CEO SAYS FREESTYLE LIBRE CAN ACHIEVE $5 BILLION IN SALES "IN A REASONABLE TIME".  Full Article

Abbott Receives U.S. Approval Of Next-Generation Mitraclip
Monday, 15 Jul 2019 

July 15 (Reuters) - Abbott Laboratories ::ABBOTT RECEIVES U.S. APPROVAL OF NEXT-GENERATION MITRACLIP®, BRINGING NEW ENHANCEMENTS TO ABBOTT'S LEADING MITRACLIP PLATFORM.ABBOTT LABORATORIES - CO HAS RECEIVED U.S. FDA APPROVAL FOR MOST ADVANCED MITRACLIP HEART VALVE REPAIR DEVICE TO TREAT MITRAL REGURGITATION.  Full Article

Enzo Biochem Says CO Considering All Available Options For Challenging Federal Circuit Panel's Decision
Friday, 21 Jun 2019 

June 21 (Reuters) - Abbott Laboratories ::ENZO BIOCHEM - U.S. COURT OF APPEALS ISSUED OPINION AFFIRMING LOWER COURT JUDGMENTS OF PATENT INVALIDITY FOR U.S. PATENT NOS. 6,992,180 & 8,097,405.ENZO BIOCHEM INC - COMPANY IS CONSIDERING ALL AVAILABLE OPTIONS FOR CHALLENGING FEDERAL CIRCUIT PANEL'S DECISION.  Full Article

New Data for Abbott's HeartMate 3 Highlights Unparalleled Performance of Industry's Leading Heart Pump
Sunday, 17 Mar 2019 

March 17 (Reuters) - Abbott Laboratories ::MOMENTUM 3 MET ITS PRIMARY ENDPOINT OF EVENT FREE SURVIVAL WHILE SHOWCASING IMPROVED RATES OF OVERALL SURVIVAL.  Full Article

Roger Bird, Svp Of Abbott Laboratories Reports Open Market Sale Of 9,188 Shares Of Co Priced Between $79.061-$79.0714- SEC Filing
Thursday, 14 Mar 2019 

March 14 (Reuters) - Abbott Laboratories ::ROGER BIRD, SVP OF ABBOTT LABORATORIES REPORTED OPEN MARKET SALE OF 9,188 SHARES OF CO PRICED BETWEEN $79.061-$79.0714 ON MARCH 13 - SEC FILING.  Full Article

FDA Approves New Indication For Abbott's Valve Repair Device
Thursday, 14 Mar 2019 

March 14 (Reuters) - FDA::FDA APPROVES NEW INDICATION FOR VALVE REPAIR DEVICE TO TREAT CERTAIN HEART FAILURE PATIENTS WITH MITRAL REGURGITATION.FDA SAYS MITRACLIP CLIP DELIVERY SYSTEM IS MANUFACTURED BY ABBOTT VASCULAR INC..  Full Article

Abbott Laboratories Says Co & Its Unit Redeemed $500 Mln In Aggregate Principal Amount Of Senior Notes - SEC Filing
Monday, 25 Feb 2019 

Feb 25 (Reuters) - Abbott Laboratories ::ABBOTT LABORATORIES - ON FEB 24, CO AND ITS UNIT, ST. JUDE MEDICAL, LLC REDEEMED $500 MILLION IN AGGREGATE PRINCIPAL AMOUNT OF SENIOR NOTES - SEC FILING.  Full Article

FDA Approves Device For Treatment Of Premature Babies & Newborns With An Opening In Their Hearts
Monday, 14 Jan 2019 

Jan 14 (Reuters) - Abbott Laboratories ::FDA APPROVES WORLD'S FIRST DEVICE FOR TREATMENT OF PREMATURE BABIES AND NEWBORNS WITH AN OPENING IN THEIR HEARTS (A COMMON CONGENITAL DEFECT).ABBOTT LABORATORIES - FDA APPROVED AMPLATZER PICCOLO OCCLUDER, A MEDICAL DEVICE THAT CAN BE IMPLANTED IN TINIEST BABIES.  Full Article

Abbott Laboratories Says Projected Sales Greater Than $1 Bln In 2018 For Glucose Monitor Freestyle Libre
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Abbott Laboratories ::SAYS PROJECTED SALES GREATER THAN $1 BILLION IN 2018 FOR GLUCOSE MONITOR FREESTYLE LIBRE - CONF CALL.SAYS WAS ABLE TO PAYDOWN $8 BILLION DEBT IN THE PAST YEAR THAT CO ASSUMED AFTER ACQUISITIONS - CONF CALL.  Full Article

Abbott Recommends Rejection Of Mini-Tender Offer By Baker Mills
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - Abbott Laboratories ::ABBOTT RECOMMENDS REJECTION OF BELOW-MARKET MINI-TENDER OFFER BY BAKER MILLS LLC.ABBOTT LABORATORIES - RECEIVED NOTICE OF UNSOLICITED MINI-TENDER OFFER BY BAKER MILLS TO PURCHASE UP TO 60,000 ABBOTT COMMON SHARES.ABBOTT LABORATORIES - BAKER MILLS' OFFER PRICE OF $57.00 PER SHARE IN CASH.ABBOTT LABORATORIES - OFFER IS CURRENTLY SCHEDULED TO EXPIRE AT 5 P.M. NEW YORK CITY TIME ON MONDAY, DEC. 12, 2018.  Full Article

CORRECTED-Samsung Bioepis Humira biosimilar wins FDA approval

July 23 The U.S. Food and Drug Administration approved Samsung Bioepis Co Ltd's biosimilar to AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira, the health agency said on Tuesday.